Literature DB >> 33968389

Anticoagulation Management in Patients With Atrial Fibrillation and Cirrhosis.

Abhishek Shenoy1,2, David Jarava3, Matthew J Stotts4, Nicolas M Intagliata4.   

Abstract

Entities:  

Year:  2021        PMID： 33968389      PMCID： PMC8087924          DOI： 10.1002/cld.1048

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  25 in total

1.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

2.  Oral rivaroxaban for symptomatic venous thromboembolism.

Authors:  Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal:  N Engl J Med       Date:  2010-12-03       Impact factor: 91.245

3.  Direct oral anticoagulants in patients with liver cirrhosis: A systematic review.

Authors:  Evert Willian Hoolwerf; Noémie Kraaijpoel; Harry Roger Büller; Nick van Es
Journal:  Thromb Res       Date:  2018-08-17       Impact factor: 3.944

4.  Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.

Authors:  Gregory Y H Lip
Journal:  Am J Med       Date:  2010-09-29       Impact factor: 4.965

5.  Cirrhosis is a risk factor for atrial fibrillation: A nationwide, population-based study.

Authors:  HyunJung Lee; Eue-Keun Choi; Tae-Min Rhee; So-Ryoung Lee; Woo-Hyun Lim; Si-Hyuck Kang; Kyung-Do Han; Myung-Jin Cha; Seil Oh
Journal:  Liver Int       Date:  2017-05-26       Impact factor: 5.828

6.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

Authors:  Gregory Y H Lip; Robby Nieuwlaat; Ron Pisters; Deirdre A Lane; Harry J G M Crijns
Journal:  Chest       Date:  2009-09-17       Impact factor: 9.410

Review 7.  Direct Oral Anticoagulants in Cirrhosis.

Authors:  Nicolas M Intagliata; Hillary Maitland; Stephen H Caldwell
Journal:  Curr Treat Options Gastroenterol       Date:  2016-06

8.  Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation.

Authors:  Marina Serper; Ethan M Weinberg; Jordana B Cohen; Peter P Reese; Tamar H Taddei; David E Kaplan
Journal:  Hepatology       Date:  2020-11-09       Impact factor: 17.425

9.  Risks Versus Benefits of Anticoagulation for Atrial Fibrillation in Cirrhotic Patients.

Authors:  Jonggi Choi; Junhwan Kim; Ju Hyun Shim; Minsu Kim; Gi-Byoung Nam
Journal:  J Cardiovasc Pharmacol       Date:  2017-10       Impact factor: 3.105

10.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Authors:  Deborah M Siegal; John T Curnutte; Stuart J Connolly; Genmin Lu; Pamela B Conley; Brian L Wiens; Vandana S Mathur; Janice Castillo; Michele D Bronson; Janet M Leeds; Florie A Mar; Alex Gold; Mark A Crowther
Journal:  N Engl J Med       Date:  2015-11-11       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.